• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性手术后胆道癌患者的强化随访计划和肿瘤学结局:一家三级医疗中心的 20 年经验。

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.

机构信息

Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.

Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138 Bologna, Italy.

出版信息

Curr Oncol. 2022 Jul 19;29(7):5084-5090. doi: 10.3390/curroncol29070402.

DOI:10.3390/curroncol29070402
PMID:35877262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9322137/
Abstract

AIM

The aim of this research was to assess the impact of an intensive follow-up program on BTC patients who had received surgery with curative intent at a tertiary referral hospital.

METHODS

BTC patients were followed-up every three months during the first two years after their first surgery and every six months from the third to the fifth post-operative year.

RESULTS

A total of 278 BTC patients who received R0/R1 surgery were included. A total of 17.7% of patients underwent a second surgery following disease relapse, and none of these patients experienced additional disease relapse.

CONCLUSIONS

An intensive follow-up after surgical resection may help in the early identification of disease relapse, leading to early treatment and prolonged survival in selected cases.

摘要

目的

本研究旨在评估在一家三级转诊医院接受根治性手术的 BTC 患者强化随访方案的效果。

方法

BTC 患者在首次手术后的前两年每三个月随访一次,第三至第五年每六个月随访一次。

结果

共纳入 278 例接受 R0/R1 手术的 BTC 患者。共有 17.7%的患者在疾病复发后接受了二次手术,这些患者均未出现疾病的进一步复发。

结论

对接受手术切除的患者进行强化随访有助于早期发现疾病复发,在某些情况下进行早期治疗和延长生存时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/9322137/5fee164016a8/curroncol-29-00402-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/9322137/83f168dea8ec/curroncol-29-00402-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/9322137/5fee164016a8/curroncol-29-00402-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/9322137/83f168dea8ec/curroncol-29-00402-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e788/9322137/5fee164016a8/curroncol-29-00402-g002.jpg

相似文献

1
Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.根治性手术后胆道癌患者的强化随访计划和肿瘤学结局:一家三级医疗中心的 20 年经验。
Curr Oncol. 2022 Jul 19;29(7):5084-5090. doi: 10.3390/curroncol29070402.
2
The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.基于氟嘧啶的辅助化疗对R0切除术后胆道癌的疗效。
Chin J Cancer. 2017 Jan 13;36(1):9. doi: 10.1186/s40880-017-0182-y.
3
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.R0 切除术而非 R1/R2 切除术与胆道癌患者的生存改善相关,优于姑息性光动力疗法。
Liver Int. 2011 Jan;31(1):99-107. doi: 10.1111/j.1478-3231.2010.02345.x. Epub 2010 Sep 16.
4
Oncological outcomes of surgery for recurrent biliary tract cancer: who are the best candidates?复发性胆道癌手术的肿瘤学结果:哪些是最佳候选者?
HPB (Oxford). 2021 Sep;23(9):1371-1382. doi: 10.1016/j.hpb.2021.01.007. Epub 2021 Jan 22.
5
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients.胆道癌的多基因突变分析与手术切除患者的复发模式有关。
Updates Surg. 2020 Mar;72(1):119-128. doi: 10.1007/s13304-020-00718-5. Epub 2020 Feb 4.
6
Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.根治性手术后肝门部胆管癌早期复发的定义:来自美国肝外胆管恶性肿瘤联盟的多机构研究
World J Surg. 2018 Sep;42(9):2919-2929. doi: 10.1007/s00268-018-4530-0.
7
Prognostic impact of lung recurrence in patients with biliary tract cancer.胆管癌患者肺部复发的预后影响
Langenbecks Arch Surg. 2023 Jul 31;408(1):290. doi: 10.1007/s00423-023-03015-y.
8
A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer.胆道癌切除术后术后结构化随访潜在获益的批判性评价。
HPB (Oxford). 2024 Feb;26(2):179-187. doi: 10.1016/j.hpb.2023.10.004. Epub 2023 Oct 11.
9
Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis.基于局部区域治疗结果的胆道癌寡转移复发的定义建议:倾向评分分层分析。
Ann Surg Oncol. 2020 Jun;27(6):1908-1917. doi: 10.1245/s10434-020-08207-0. Epub 2020 Jan 14.
10
Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature.复发性胆管癌手术的生存率:单中心经验及文献系统综述
Jpn J Clin Oncol. 2017 Mar 1;47(3):206-212. doi: 10.1093/jjco/hyw182.

引用本文的文献

1
Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.胆管癌化疗之外:深入剖析TOPAZ-1试验的最新长期随访数据
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.
2
Post-operative Surveillance and Management of Intrahepatic Cholangiocarcinoma Using Circulating Tumor DNA: A Case Report.利用循环肿瘤DNA对肝内胆管癌进行术后监测与管理:一例报告
Cureus. 2024 Mar 10;16(3):e55914. doi: 10.7759/cureus.55914. eCollection 2024 Mar.
3
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).

本文引用的文献

1
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.阳性淋巴结和切缘状态对切除的肝门部胆管癌患者总生存的影响:ENSCCA注册研究
Cancers (Basel). 2022 May 12;14(10):2389. doi: 10.3390/cancers14102389.
2
Cholangiocarcinoma.胆管癌。
Nat Rev Dis Primers. 2021 Sep 9;7(1):65. doi: 10.1038/s41572-021-00300-2.
3
Recurrence after Curative Resection for Intrahepatic Cholangiocarcinoma: How to Predict the Chance of Repeat Hepatectomy?
肿瘤免疫微环境与胆管癌的当前免疫治疗(综述)。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27.
肝内胆管癌根治性切除术后复发:如何预测再次肝切除的机会?
J Clin Med. 2021 Jun 26;10(13):2820. doi: 10.3390/jcm10132820.
4
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".ABC-02 试验十年后晚期胆道癌的一线化疗:“但它仍在前行!”。
Cancer Treat Res Commun. 2021;27:100335. doi: 10.1016/j.ctarc.2021.100335. Epub 2021 Feb 11.
5
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.切除术后胆道癌辅助全身治疗的陷阱、挑战和更新。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):547-554. doi: 10.1080/17474124.2021.1890031. Epub 2021 Feb 19.
6
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.BILCAP 试验与可切除胆道癌的辅助卡培他滨治疗:对一种标准治疗方案的思考。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485. doi: 10.1080/17474124.2021.1864325. Epub 2020 Dec 18.
7
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020:机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
8
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.胆道癌的辅助化疗:现状与未来展望。
Curr Opin Oncol. 2020 Jul;32(4):364-369. doi: 10.1097/CCO.0000000000000643.
9
Current standards and future perspectives in adjuvant treatment for biliary tract cancers.当前胆道癌辅助治疗的标准和未来展望。
Cancer Treat Rev. 2020 Mar;84:101936. doi: 10.1016/j.ctrv.2019.101936. Epub 2019 Dec 4.
10
Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma.肝切除术与栓塞术治疗复发性肝细胞癌。
World J Surg. 2020 Jan;44(1):232-240. doi: 10.1007/s00268-019-05225-2.